{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:38:49Z","timestamp":1794375529273,"version":"4.9.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8136","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,10,15]]},"DOI":"10.1038\/s41586-026-10971-0","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:01:35Z","timestamp":1787756495000},"page":"785-794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A binding-to-release strategy for targeted anticancer drug delivery"],"prefix":"10.1038","volume":"658","author":[{"given":"Zihao","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6588-4757","authenticated-orcid":false,"given":"Ziren","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8129-1473","authenticated-orcid":false,"given":"Junyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Yang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuedan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changlun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1438-0062","authenticated-orcid":false,"given":"Zhibo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"10971_CR1","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M. & de Vries, E. G. E. The journey of antibody\u2013drug conjugates: lessons learned from 40 years of development. Cancer Discov. 14, 2089\u20132108 (2024).","journal-title":"Cancer Discov."},{"key":"10971_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama, K., Anami, Y., Ha, S. Y. Y. & Yamazaki, C. M. Exploring the next generation of antibody\u2013drug conjugates. Nat. Rev. Clin. Oncol. 21, 203\u2013223 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10971_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck, A., Goetsch, L., Dumontet, C. & Corva\u00efa, N. Strategies and challenges for the next generation of antibody\u2013drug conjugates. Nat. Rev. Drug Discov. 16, 315\u2013337 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10971_CR4","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).","journal-title":"Science"},{"key":"10971_CR5","doi-asserted-by":"crossref","unstructured":"Ashburner, M. et al. Gene Ontology: tool for the unification of biology. Nat. Genet. 25, 25\u201329 (2000).","DOI":"10.1038\/75556"},{"key":"10971_CR6","doi-asserted-by":"crossref","unstructured":"The Gene Ontology Consortium. The Gene Ontology knowledgebase in 2026. Nucleic Acids Res. 54, D1779\u2013D1792 (2026).","DOI":"10.1093\/nar\/gkag678"},{"key":"10971_CR7","doi-asserted-by":"crossref","unstructured":"Carbon, S. et al. AmiGO: online access to ontology and annotation data. Bioinformatics 25, 288\u2013289 (2009).","DOI":"10.1093\/bioinformatics\/btn615"},{"key":"10971_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrc2394","volume":"8","author":"K Strebhardt","year":"2008","unstructured":"Strebhardt, K. & Ullrich, A. Paul Ehrlich\u2019s magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8, 473\u2013480 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"10971_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/d41573-024-00064-w","volume":"23","author":"P Flynn","year":"2024","unstructured":"Flynn, P., Suryaprakash, S., Grossman, D., Panier, V. & Wu, J. The antibody\u2013drug conjugate landscape. Nat. Rev. Drug Discov. 23, 577\u2013578 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10971_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago, J. Z., Modi, S. & Chandarlapaty, S. Unlocking the potential of antibody\u2013drug conjugates for cancer therapy. Nat. Rev. Clin. Oncol. 18, 327\u2013344 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10971_CR11","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M. & Beck, A. Antibody\u2013drug conjugates come of age in oncology. Nat. Rev. Drug Discov. 22, 641\u2013661 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10971_CR12","doi-asserted-by":"publisher","first-page":"9182","DOI":"10.1039\/D2CS00446A","volume":"51","author":"N Ashman","year":"2022","unstructured":"Ashman, N., Bargh, J. D. & Spring, D. R. Non-internalising antibody\u2013drug conjugates. Chem. Soc. Rev. 51, 9182\u20139202 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"10971_CR13","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.cell.2026.04.016","volume":"189","author":"L Conilh","year":"2026","unstructured":"Conilh, L., Metrangolo, V., Crescioli, S., Reichert, J. M. & Dumontet, C. Navigating the clinical progress of antibody-drug conjugates: emerging opportunities and remaining challenges. Cell 189, 2791\u20132820 (2026).","journal-title":"Cell"},{"key":"10971_CR14","doi-asserted-by":"publisher","first-page":"2229101","DOI":"10.1080\/19420862.2023.2229101","volume":"15","author":"H Maecker","year":"2023","unstructured":"Maecker, H., Jonnalagadda, V., Bhakta, S., Jammalamadaka, V. & Junutula, J. R. Exploration of the antibody\u2013drug conjugate clinical landscape. mAbs 15, 2229101 (2023).","journal-title":"mAbs"},{"key":"10971_CR15","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jconrel.2025.01.060","volume":"380","author":"Y Sung","year":"2025","unstructured":"Sung, Y., Choi, Y., Kim, E. S., Ryu, J. H. & Kwon, I. C. Receptor-ligand interactions for optimized endocytosis in targeted therapies. J. Control. Release 380, 524\u2013538 (2025).","journal-title":"J. Control. Release"},{"key":"10971_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41568-023-00574-6","volume":"23","author":"B Banushi","year":"2023","unstructured":"Banushi, B., Joseph, S. R., Lum, B., Lee, J. J. & Simpson, F. Endocytosis in cancer and cancer therapy. Nat. Rev. Cancer 23, 450\u2013473 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"10971_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58266-8","volume":"16","author":"L-C Tsao","year":"2025","unstructured":"Tsao, L.-C. et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat. Commun. 16, 3167 (2025).","journal-title":"Nat. Commun."},{"key":"10971_CR18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/prca.201300095","volume":"8","author":"EJ Hamson","year":"2014","unstructured":"Hamson, E. J., Keane, F. M., Tholen, S., Schilling, O. & Gorrell, M. D. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin. Appl. 8, 454\u2013463 (2014).","journal-title":"Proteomics Clin. Appl."},{"key":"10971_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil, C. et al. 68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J. Nucl. Med. 60, 801\u2013805 (2019).","journal-title":"J. Nucl. Med."},{"key":"10971_CR20","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-19-2238","volume":"26","author":"M Fabre","year":"2020","unstructured":"Fabre, M. et al. OMTX705, a novel FAP-targeting ADC demonstrates activity in chemotherapy and pembrolizumab-resistant solid tumor models. Clin. Cancer Res. 26, 3420\u20133430 (2020).","journal-title":"Clin. Cancer Res."},{"key":"10971_CR21","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.2967\/jnumed.122.264036","volume":"63","author":"A Galbiati","year":"2022","unstructured":"Galbiati, A. et al. A dimeric FAP-targeting small-molecule radioconjugate with high and prolonged tumor uptake. J. Nucl. Med. 63, 1852\u20131858 (2022).","journal-title":"J. Nucl. Med."},{"key":"10971_CR22","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1200\/JCO.2025.43.16_suppl.3028","volume":"43","author":"J Torres-Jim\u00e9nez","year":"2025","unstructured":"Torres-Jim\u00e9nez, J. et al. First-in-human phase 1 dose escalation trial of OMTX705, a novel anti-fibroblast activation protein (FAP) antibody drug conjugate (ADC), in monotherapy and in combination with pembrolizumab in patients with solid tumors. J. Clin. Oncol. 43, 3028\u00a0https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3028 (2025).","journal-title":"J. Clin. Oncol."},{"key":"10971_CR23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nchembio.157","volume":"5","author":"S Tsukiji","year":"2009","unstructured":"Tsukiji, S., Miyagawa, M., Takaoka, Y., Tamura, T. & Hamachi, I. Ligand-directed tosyl chemistry for protein labeling in vivo. Nat. Chem. Biol. 5, 341\u2013343 (2009).","journal-title":"Nat. Chem. Biol."},{"key":"10971_CR24","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1021\/jacs.8b11747","volume":"141","author":"T Tamura","year":"2019","unstructured":"Tamura, T. & Hamachi, I. Chemistry for covalent modification of endogenous\/native proteins: from test tubes to complex biological systems. J. Am. Chem. Soc. 141, 2782\u20132799 (2019).","journal-title":"J. Am. Chem. Soc."},{"key":"10971_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","volume":"630","author":"X-Y Cui","year":"2024","unstructured":"Cui, X.-Y. et al. Covalent targeted radioligands potentiate radionuclide therapy. Nature 630, 206\u2013213 (2024).","journal-title":"Nature"},{"key":"10971_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cell.2020.05.028","volume":"182","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. Developing covalent protein drugs via proximity-enabled reactive therapeutics. Cell 182, 85\u201397.e16 (2020).","journal-title":"Cell"},{"key":"10971_CR27","doi-asserted-by":"publisher","first-page":"9430","DOI":"10.1002\/anie.201309399","volume":"53","author":"J Dong","year":"2014","unstructured":"Dong, J., Krasnova, L., Finn, M. G. & Sharpless, K. B. Sulfur(VI) fluoride exchange (SuFEx): another good reaction for click chemistry. Angew. Chem. Int. Ed. 53, 9430\u20139448 (2014).","journal-title":"Angew. Chem. Int. Ed."},{"key":"10971_CR28","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.1039\/C8CS00960K","volume":"48","author":"AS Barrow","year":"2019","unstructured":"Barrow, A. S. et al. The growing applications of SuFEx click chemistry. Chem. Soc. Rev. 48, 4731\u20134758 (2019).","journal-title":"Chem. Soc. Rev."},{"key":"10971_CR29","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1021\/bc0600214","volume":"17","author":"SC Jeffrey","year":"2006","unstructured":"Jeffrey, S. C. et al. Development and properties of \u03b2-glucuronide linkers for monoclonal antibody\u2212drug conjugates. Bioconj. Chem. 17, 831\u2013840 (2006).","journal-title":"Bioconj. Chem."},{"key":"10971_CR30","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1126\/science.2434996","volume":"235","author":"FH Westheimer","year":"1987","unstructured":"Westheimer, F. H. Why nature chose phosphates. Science 235, 1173\u20131178 (1987).","journal-title":"Science"},{"key":"10971_CR31","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher, A. H. & Brown, M. P. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br. J. Cancer 117, 1736\u20131742 (2017).","journal-title":"Br. J. Cancer"},{"key":"10971_CR32","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nchembio.2007.26","volume":"3","author":"G Blum","year":"2007","unstructured":"Blum, G., von Degenfeld, G., Merchant, M. J., Blau, H. M. & Bogyo, M. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat. Chem. Biol. 3, 668\u2013677 (2007).","journal-title":"Nat. Chem. Biol."},{"key":"10971_CR33","doi-asserted-by":"publisher","first-page":"320ra324","DOI":"10.1126\/scitranslmed.aad0293","volume":"8","author":"MJ Whitley","year":"2016","unstructured":"Whitley, M. J. et al. A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Sci. Transl. Med. 8, 320ra324\u2013320ra324 (2016).","journal-title":"Sci. Transl. Med."},{"key":"10971_CR34","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-24-0897","volume":"15","author":"Z Kong","year":"2025","unstructured":"Kong, Z. et al. CTR-FAPI PET enables precision management of medullary thyroid carcinoma. Cancer Discov. 15, 316\u2013328 (2025).","journal-title":"Cancer Discov."},{"key":"10971_CR35","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1016\/S0960-894X(98)00609-X","volume":"8","author":"GM Dubowchik","year":"1998","unstructured":"Dubowchik, G. M. & Firestone, R. A. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg. Med. Chem. Lett. 8, 3341\u20133346 (1998).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10971_CR36","doi-asserted-by":"publisher","first-page":"5440","DOI":"10.1158\/1078-0432.CCR-22-1788","volume":"28","author":"A Zana","year":"2022","unstructured":"Zana, A. et al. Fibroblast activation protein triggers release of drug payload from non-internalizing small molecule drug conjugates in solid tumors. Clin. Cancer Res. 28, 5440\u20135454 (2022).","journal-title":"Clin. Cancer Res."},{"key":"10971_CR37","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","volume":"405","author":"TF Stoop","year":"2025","unstructured":"Stoop, T. F. et al. Pancreatic cancer. Lancet 405, 1182\u20131202 (2025).","journal-title":"Lancet"},{"key":"10971_CR38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41570-019-0159-2","volume":"4","author":"C Sohrabi","year":"2020","unstructured":"Sohrabi, C., Foster, A. & Tavassoli, A. Methods for generating and screening libraries of genetically encoded cyclic peptides in drug discovery. Nat. Rev. Chem. 4, 90\u2013101 (2020).","journal-title":"Nat. Rev. Chem."},{"key":"10971_CR39","doi-asserted-by":"publisher","first-page":"27095","DOI":"10.1021\/jacs.5c10625","volume":"147","author":"Y Yang","year":"2025","unstructured":"Yang, Y. et al. Ribosomal incorporation of fluorosulfonyloxy-l-phenylalanine into macrocyclic peptides for de novo target-specific covalent binders. J. Am. Chem. Soc. 147, 27095\u201327104 (2025).","journal-title":"J. Am. Chem. Soc."},{"key":"10971_CR40","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1021\/acs.accounts.6b00491","volume":"50","author":"Z Liu","year":"2017","unstructured":"Liu, Z. et al. Forging the Basis for Developing protein\u2013ligand interaction scoring functions. Acc. Chem. Res. 50, 302\u2013309 (2017).","journal-title":"Acc. Chem. Res."},{"key":"10971_CR41","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1021\/jm048957q","volume":"48","author":"R Wang","year":"2005","unstructured":"Wang, R., Fang, X., Lu, Y., Yang, C.-Y. & Wang, S. The PDBbind database: methodologies and updates. J. Med. Chem. 48, 4111\u20134119 (2005).","journal-title":"J. Med. Chem."},{"key":"10971_CR42","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/bioinformatics\/btu626","volume":"31","author":"Z Liu","year":"2015","unstructured":"Liu, Z. et al. PDB-wide collection of binding data: current status of the PDBbind database. Bioinformatics 31, 405\u2013412 (2015).","journal-title":"Bioinformatics"},{"key":"10971_CR43","doi-asserted-by":"publisher","first-page":"35638","DOI":"10.1021\/jacs.5c11292","volume":"147","author":"X Cheng","year":"2025","unstructured":"Cheng, X. et al. Multicyclic peptides targeting PD-L1 for radiotheranostics: from discovery to clinical proof-of-concept. J. Am. Chem. Soc. 147, 35638\u201335654 (2025).","journal-title":"J. Am. Chem. Soc."},{"key":"10971_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113738","volume":"382","author":"HK Lee","year":"2025","unstructured":"Lee, H. K. et al. Enhancing the bystander effect of antibody-drug conjugate by using a novel caspase-3 cleavable peptide linker to overcome tumor heterogeneity. J. Control. Release 382, 113738 (2025).","journal-title":"J. Control. Release"},{"key":"10971_CR45","doi-asserted-by":"publisher","first-page":"19871","DOI":"10.1021\/acs.jmedchem.5c01982","volume":"68","author":"S Li","year":"2025","unstructured":"Li, S., Guo, Y., Che, J., Dai, H. & Dong, X. Recent advances in peptide linkers for antibody-drug conjugates. J. Med. Chem. 68, 19871\u201319892 (2025).","journal-title":"J. Med. Chem."},{"key":"10971_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03880-y","volume":"9","author":"R Rossin","year":"2018","unstructured":"Rossin, R. et al. Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice. Nat. Commun. 9, 1484 (2018).","journal-title":"Nat. Commun."},{"key":"10971_CR47","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","volume":"40","author":"R Colombo","year":"2022","unstructured":"Colombo, R. & Rich, J. R. The therapeutic window of antibody drug conjugates: a dogma in need of revision. Cancer Cell 40, 1255\u20131263 (2022).","journal-title":"Cancer Cell"},{"key":"10971_CR48","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/cbic.201900126","volume":"20","author":"C Wang","year":"2019","unstructured":"Wang, C., Abegg, D., Dwyer, B. G. & Adibekian, A. Discovery and evaluation of new activity-based probes for serine hydrolases. ChemBioChem 20, 2212\u20132216 (2019).","journal-title":"ChemBioChem"},{"key":"10971_CR49","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2967\/jnumed.121.262533","volume":"63","author":"M Xu","year":"2022","unstructured":"Xu, M. et al. Albumin binder\u2013conjugated fibroblast activation protein inhibitor radiopharmaceuticals for cancer therapy. J. Nucl. Med. 63, 952\u2013958 (2022).","journal-title":"J. Nucl. Med."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10971-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10971-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10971-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:51:22Z","timestamp":1792122682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10971-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":49,"journal-issue":{"issue":"8136","published-print":{"date-parts":[[2026,10,15]]}},"alternative-id":["10971"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-10971-0","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z.L., Z.W. and X.-Y.C. are co-inventors on a relevant patent application (PCT\/CN2025\/075553) filed by Peking University. Z.L. is a co-founder of and scientific advisor for BoomRay Pharmaceuticals. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}